From: Sent: To:	(CAB-KAT 18 September 2015 10:38	(CAB-KATAINEN) 18 September 2015 10:38			
Cc:	; (CAB-KATAINEN);	(SG);	(SG); (CAB-KATAINEN);		
Subject:	(CAB-KATAINEN) RE: Meeting with ECPA				
Dear Ms ,					
· · · · · · · · · · · · · · · · · · ·	ail. I have been in contact with I ers in the Secretariat General, a		and Mr e happy to meet with you.	who are	
I have put them in copy meeting.	to this email and I would advis	se you to cont	act them in order to set up	а	
Best					
Member of Cabinet Cabinet of Vice President Jyl Jobs, Growth, Investment ar					
European Commission BERL 10/ B-1049 Brussels/Belgium Office: +32 2 29 Mobile: +32	a.eu				
From: Sent: Monday, To: Cc: Subject: Meet	[mailto September 14, 2015 5:21 PM (CAB-KATAINEN) ing with ECPA	@ecpa.eu]			
Ms ,					
ECPA is facing i plant protectio increased and o update you on	n a meeting with Mr mportant hurdles preventing or n products on the market in a ti call for an urgent solution, we w the new procedural obstacles w setting of Maximum Residue Le	ur member co imely manner vould like to k vhich our mer	. Since these hurdles recer indly request a meeting in nbers reported on, especia	vative ntly order to ally	

 On the interim definition of Endocrine Disruption which is not scientifically based and may hit safe active substances

For such a meeting we would like to propose the following times:

- Friday 18th September, between 1500-1700 hours
- Monday 21st September, before 1500 hours
- Tuesday 22nd September, all day
- Wednesday 23rd September, before 1500 hours

ECPA would be represented by Euros Jones and myself. We hope that you will be able to reply positively to this request,

Best regards,



## **ECPA** aisbl

6 Avenue E. Van Nieuwenhuyse 1160 Brussels, Belgium

Tel: +32 2 Fax: +32 2

www.ecpa.eu

EU Transparency Register ID N° 0711626572-26

From:

Sent: 22 April 2015 17:44

**To:** @ec.europa.eu' **Subject:** Meeting with ECPA: Follow-up

Dear

Thank you for your time yesterday. I found it useful and I hope that the information on our sector was useful. I appreciated your particular focus on innovation as this is a key area for our companies; as I mentioned, the R&D budget exceeds €2 billion annually - but with a growing percentage being focussed on non-EU markets. If I can provide any additional information, please let me know.

We also briefly discussed the new procedures and the impact on the decision making procedure on decision making, with the impact being a delay in the entry onto the market of new innovation. We hope that delays will only be short term but as I mentioned, we do plan to write to Commissioner Timmermans on this issue and we will of course keep you informed.

We only had a brief moment to discuss endocrine disruptors and as mentioned, this is very much in the assessment phase in DG SANTE at the moment. But I would welcome the opportunity to further discuss this issue with you when the assessment nears completion.

If you require any additional information, please do not hesitate to contact me.

Thanks again and best regards

**European Crop Protection Association, aisbl** 

Tel: +32 2 (direct); +32 2 (reception)

Tel: +32 (GSM - Mobile)

EU Transparency Register ID N° 0711626572-26

